Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?

Objectives To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urology (Ridgewood, N.J.) N.J.), 2009-10, Vol.74 (4), p.842-845
Hauptverfasser: Crépel, Maxime, Isbarn, Hendrik, Capitanio, Umberto, Liberman, Daniel, Jeldres, Claudio, Sun, Maxine, Shariat, Shahrokh F, Widmer, Hugues, Arjane, Philippe, Graefen, Markus, Montorsi, Francesco, Patard, Jean-Jacques, Perrotte, Paul, Karakiewicz, Pierre I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. Methods We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. Results At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. Conclusions Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.
ISSN:0090-4295
1527-9995
DOI:10.1016/j.urology.2009.02.013